Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women

ConclusionsThese data support the potential usage of antiprogestins for primary prevention of poor-prognostic breast cancers.Trial registrationClinical trial 1Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control – a randomized controlled trial, clinicaltrialsregister.eu,2009-009014-40; registered on 20 July 2009.Clinical trial 2The effect of a progesterone receptor modulator on breast tissue in women with BRCA1 and 2 mutations, clinicaltrials.gov,NCT01898312; registered on 07 May 2013.Clinical trial 3A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk,  clinicaltrialsregister.eu,2015-001587-19; registered on  15 July 2015.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research